Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.5K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.5K
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

5.0K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
5.0K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

733
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
733
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.6K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.6K
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations01:26

Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations

599
Renal calculi, commonly termed kidney stones, are crystalline solid masses that form in the kidneys but can occur at any point within the urinary system, encompassing the kidneys, ureters, bladder, and urethra.The pathophysiology of renal stones involves several key factors: supersaturation of the urine with stone-forming constituents, changes in urine pH, a decrease in urine volume, and the presence of substances that promote or inhibit stone formation.Supersaturation of Urine: This is the...
599
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

657
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
657

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiopulmonary transit time measured on dynamic rubidium cardiac PET/CT is a predictor for pulmonary hypertension.

EJNMMI research·2026
Same author

Evaluating the Whole Patient: Lessons from the Pre-CKM Era Toward Integrated Cardio-Kidney-Liver-Metabolic Care.

Life (Basel, Switzerland)·2026
Same author

An expert opinion on heart failure in hypertensive heart disease.

European journal of heart failure·2026
Same author

Untreated, uncontrolled and below-target hypertension in southern Africa: a population-based prevalence and care cascade assessment in rural Lesotho.

BMJ global health·2026
Same author

Lay community health worker-led care with mobile decision support for uncontrolled hypertension: a cluster-randomized trial.

Nature medicine·2026
Same author

[Primary hyperaldosteronism - screening, work-up, treatment].

Praxis·2026

Related Experiment Video

Updated: Mar 23, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.4K

[Hyperuricemia, gout and cardiovascular diseases].

Karsten Murray1,2, Thilo Burkard1,2

  • 11 Abteilung für Kardiologie, Universitätsspital Basel.

Therapeutische Umschau. Revue Therapeutique
|March 24, 2016
PubMed
Summary

High uric acid levels and gout are linked to cardiovascular issues. Clinicians should manage cardiovascular risk factors in these patients, but preventive urate-lowering treatment is only advised in specific cases.

More Related Videos

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

20.6K

Related Experiment Videos

Last Updated: Mar 23, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.4K
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

20.6K

Area of Science:

  • Cardiology
  • Rheumatology
  • Metabolic Diseases

Context:

  • Hyperuricemia and gout frequently coexist with arterial hypertension and metabolic syndrome.
  • These conditions are associated with significant cardiovascular comorbidities and elevated cardiovascular risk.
  • The independent and causal nature of this association requires further investigation.

Purpose:

  • To review the clinical implications of hyperuricemia and gout in patients with cardiovascular comorbidities.
  • To emphasize the importance of managing cardiovascular risk factors in patients with hyperuricemia and gout.
  • To discuss the current evidence and recommendations regarding urate-lowering therapy for cardiovascular risk reduction.

Summary:

  • Hyperuricemia and gout are prevalent conditions often seen with hypertension and metabolic syndrome, carrying a high cardiovascular risk.
  • While pathophysiological links exist, the independent and causal relationship between hyperuricemia/gout and cardiovascular disease needs clarification.
  • Comprehensive identification and treatment of cardiovascular risk factors are crucial for all patients with hyperuricemia and gout.

Impact:

  • Highlights the need for integrated management of metabolic and cardiovascular health.
  • Informs clinical practice regarding risk assessment and treatment strategies for patients with hyperuricemia and gout.
  • Underscores the limited current indications for preventive urate-lowering therapy in asymptomatic hyperuricemia concerning cardiovascular outcomes.